This trial is for those with a diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based therapy. It is an open label study, which means that both you and your doctor will know what treatment you are receiving.The researchers conducting the trial are testing a new treatment ca…

Researchers in this study are trying to find out if treating platinum resistant ovarian cancer with an immunotherapy drug called embrolizumab and the chemotherapy drug paclitaxel is better than just treating with paclitaxel on it’s own. Platinum resistance means that your cancer no longer responds to platinum based chemotherapy (e.g carboplatin). …

The purpose of this study is to determine if a combination of two different anti-cancer drugs are safe and effective in treating different types of solid tumours, including ovarian cancer. It's for women with ovarian cancer whose cancer has continued to spread and grow despite standard chemotherapy treatments. The drugs involved in this trial are k…

The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

In cases where ovarian, fallopian tube or peritoneal cancer has come back (recurrence or relapse) and it has become resistant to platinum-based chemotherapy, new treatment strategies and new drugs are needed to better treat this disease. This study tests a new drug both in combination with a known treatment and alone, to find out if the differe…

Researchers are conducting the PROMPT trial to see if the study drug (pembrolizumab) can be used as a maintenance treatment to slow the growth/return of cancer after treatment with paclitaxel (standard chemotherapy drug). Normally, after receiving paclitaxel, patients are observed without treatment as maintenance treatment is not standard for this …